EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial

Elliot B Tapper, Beanna Martinez, Peter Jepsen iD, Xi Chen, Neehar D Parikh iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.18127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Elliot B Tapper und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Diphosphonates, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Falls and fractures are common and morbid for patients with cirrhosis. Bisphosphonates are recommended for the prevention of fractures for people with osteoporosis cirrhosis; however, data supporting effectiveness in cirrhosis are lacking.

Aim

We sought to emulate a clinical trial of bisphosphonates in cirrhosis.

Methods

We used national Medicare data (2008–2020) to examine the 5‐year risk of fractures in patients who did or did not receive bisphosphonates with a new‐user design among people diagnosed with cirrhosis and osteoporosis. We balanced treated and untreated with inverse probability of treatment weighting, evaluated intention‐to‐treat and as‐treated effects, and examined both control exposures (statin use) and outcomes (decompensation) to test causal relationships.

Results

There were 253 and 20,888 new users and non‐users of bisphosphonates, respectively. The median age was 74 years. The most common bisphosphonate used was alendronate (73.6%). Bisphosphonates significantly reduced fractures overall (27.5% vs. 33.0%, p = 0.0004) in the intention‐to‐treat analysis, particularly for people

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisDiphosphonatesBone Density Conservation AgentsOsteoporosisHumansMaleFemaleAgedUnited StatesAged, 80 and overMedicareOsteoporotic FracturesTreatment OutcomeFractures, BoneMiddle AgedAccidental FallsAlendronate

Substanzen

DiphosphonatesBone Density Conservation AgentsAlendronate

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
  • Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, University of Aarhus, Aarhus, Denmark.

ORCID-Profile: Peter Jepsen, Neehar D Parikh

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Tapper, E. B., Martinez, B., Jepsen, P., Chen, X., & Parikh, N. D. (2024). Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18127

Vancouver

Tapper EB, Martinez B, Jepsen P, Chen X, Parikh ND. Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18127

BibTeX
@article{Tapper2024,
  author = {Tapper, Elliot B and Martinez, Beanna and Jepsen, Peter and Chen, Xi and Parikh, Neehar D},
  title = {Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.18127}
}
Kostenlos starten →